Patents Examined by Theodore R West
  • Picolinamide N-oxide compounds with fungicidal activity
    Patent number: 10111432
    Abstract: This disclosure relates to picolinamide N-oxides of Formula I and their use as fungicides.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 30, 2018
    Assignee: Dow AgroSciences LLC
    Inventors: Jared W. Rigoli, Kevin G. Meyer, Chenglin Yao, Brian A. Loy, Brannon Sam
  • Use of 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
    Patent number: 10105348
    Abstract: Use of 2-(5S-Methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide or its pharmaceutically acceptable salt in manufacture of a medicament for prophylaxis and treatment of seizure.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: October 23, 2018
    Assignee: Latvian Institute of Organic Synthesis
    Inventors: Liga Zvejniece, Maija Dambrova, Baiba Svalbe, Edijs Vavers, Ivars Kalvins, Grigorijs Veinbergs, Ilmars Stonans, Ilga Misane, Maksims Vorona, Aleksandrs Cernobrovijs
  • Inhibition of crystal growth of roflumilast
    Patent number: 10105354
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 23, 2018
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne
  • Process and compositions for achieving mammalian energy balance
    Patent number: 10085963
    Abstract: Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 2, 2018
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
  • Quick dissolving diphenhydramine oral dosage form
    Patent number: 10085954
    Abstract: An oral dosage form to deliver diphenhydramine through the sublingual or buccal mucosa. The oral dosage form can contain diphenhydramine, or a pharmaceutically acceptable salt thereof, a permeability enhancer, and a buffering agent. The buffering agent can achieve a pH of about 7.0 to about 8.0. The diphenhydramine can completely dissolve within about 2 minutes.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 2, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Richard John Dansereau, Brian Laster, Erin Swigart, Ashraf Traboulsi
  • Pharmaceutical formulation containing gelling agent
    Patent number: 10064825
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: September 4, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Semifluorinated alkane compositions
    Patent number: 10058615
    Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 28, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Bastian Theisinger, Sonja Theisinger
  • Use of lactones as odor masking agents
    Patent number: 10059908
    Abstract: Suggested is a method for masking odoriferous incorrect notes in oleochemical preparations, by adding to said compositions specific lactones.
    Type: Grant
    Filed: October 25, 2014
    Date of Patent: August 28, 2018
    Assignee: Symrise AG
    Inventors: Marcus Betzer, Hans-Georg Reindl, Nicole Schulze
  • Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
    Patent number: 10028940
    Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of plasma cells and/or B-cells, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: July 24, 2018
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Steven Dworetzky
  • Tomatidine, analogs thereof, compositions comprising same, and uses for same
    Patent number: 10022386
    Abstract: In one aspect, the invention relates to methods for promoting muscle hypertrophy or decreasing adiposity by providing to an animal in need thereof an effective amount of a compound. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 17, 2018
    Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Christopher M. Adams, Michael C. Dyle, Michael Welsh
  • Topical solution of isotretinoin
    Patent number: 10022348
    Abstract: The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and process of preparing it.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 17, 2018
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Sanjay Kumar Motwani, Vaibhav Dubey, Shashikanth Isloor, Vinod Kumar Arora, Vishnu Datta Maremanda, K. K. Janakiraman, Sumit Madan, Subodh Deshmukh
  • Caveolin-1 related methods for treating glioblastoma with temozolomide
    Patent number: 10022372
    Abstract: This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: July 17, 2018
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: Michael P. Lisanti, Jean-Francois Jasmin, Kevin Quann
  • Compounds useful for treating AIDS
    Patent number: 10017498
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R? is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n? is 1 or 2.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: July 10, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noelie Campos, Aude Garcel
  • Pharmaceutical composition of sildenafil citrate in the form of a suspension for oral use
    Patent number: 10016428
    Abstract: The present invention refers to a pharmaceutical composition of sildenafil citrate in the form of a suspension for administration orally that comprises water as a vehicle and xanthan gum and hypromellose as suspension agents, that is highly stable and allows the efficient masking of the active ingredient's bitter taste. It also refers to a procedure for the preparation of said suspension and to a container that contains it and that is provided with a dosing device for its administration. This composition of sildenafil citrate in the form of a suspension is suitable for administration orally for the treatment of masculine sexual dysfunction.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 10, 2018
    Inventors: Fernando Martínez-Alzamora, Antonia Gómez Calvo, Miguel Rizo Martínez, Nuria Sanz Menéndez
  • Alpha-branched alkenoic acids and the use of alpha-branched alkanoic and alkenoic acids as a fragrance
    Patent number: 10011554
    Abstract: The present invention refers to alpha branched alkanoic and alkenoic acids of formula (I) wherein X and R have the same meaning as given in the description. The invention further refers to perfume compositions and fragrance applications comprising them.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 3, 2018
    Assignee: Givaudan, S.A.
    Inventor: Jean-Pierre Bachmann
  • Methods for the treatment of hyperhidrosis
    Patent number: 10010494
    Abstract: The present invention relates in general to methods of treating sweating disorders and in particular to topical compositions for the treatment of hyperhidrosis. The methods of the present invention relate to the topical application of a composition comprising a therapeutically effective amount of oxybutynin, tolterodine or a substituted benzamide such as sulpiride.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: July 3, 2018
    Inventor: Menni Menashe Zinger
  • Treatment of ophthalmic conditions by selectively removing senescent cells from the eye
    Patent number: 10010546
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 3, 2018
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Compounded solutions of diclofenac and lidocaine and methods
    Patent number: 9999604
    Abstract: A compounded topical solution may include approximately 85% to approximately 95% (v/v) diclofenac sodium topical solution, 1.5% (w/w), and approximately 5% to approximately 15% (v/v) lidocaine hydrochloride topical solution, 4% USP.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 19, 2018
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Transplantation therapies
    Patent number: 9994585
    Abstract: Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: June 12, 2018
    Assignee: Aphios Corporation
    Inventors: Jonathan Steven Alexander, April C. Carpenter, Trevor Percival Castor
  • Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
    Patent number: 9993472
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: June 12, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHN HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu